Show simple item record

dc.contributor.authorPaul, Arghya
dc.contributor.authorChen, Guangyong
dc.contributor.authorKhan, Afshan Afsar
dc.contributor.authorRao, Vijayaraghava T.
dc.contributor.authorShum-Tim, Dominique
dc.contributor.authorPrakash, Satya
dc.date.accessioned2015-10-14T19:39:27Z
dc.date.available2015-10-14T19:39:27Z
dc.date.issued2012-12-01
dc.identifier.citationPrakash, Satya, Ms Wei Shao, Arghya Paul, Sana Abbasi, Parminder Chahal, Jimmy A. Mena, Johnny Montes, and Amine Kamen. "A Novel Polyethyleneimine-coated Adeno-associated Virus-like Particle Formulation for Efficient SiRNA Delivery in Breast Cancer Therapy: Preparation and in Vitro Analysis." International Journal of Nanomedicine IJN (2012): 1575. http://dx.doi.org/10.3727/096368912X637497en_US
dc.identifier.urihttp://hdl.handle.net/1808/18693
dc.description.abstractStem cell transplantation has been widely acknowledged for their immense potential in regenerative medicine. In these procedures, the implanted cells need to maintain both their viability and functional properties for effective therapeutic outcomes. This has long been a subject of major concern and intensive studies. Microencapsulation of stem cells within polymeric microcapsules can be an efficient approach to achieve this goal, particularly for heart diseases. This study reports the use of biocompatible, fluorogenic genipin-cross-linked alginate chitosan (GCAC) microcapsules in delivery of human adipose stem cells (hASCs) with an aim to increase the implant retention in the infarcted myocardium for maximum clinical benefits. In vitro results show, under hypoxic conditions, the microencapsulated cells overexpressed significantly higher amount of biologically active vascular endothelial growth factor (VEGF). We investigated on the in vivo potential using immunocompetent female rats after induction of myocardial infarction. For this, animal groups (n = 8) received empty control microcapsules, 1.5 × 106 free male hASCs, or 1.5 × 106 microencapsulated male hASCs. Results show significant retention (3.5 times higher) of microencapsulated hASCs compared to free hASCs after 10 weeks of transplantation. Microencapsulated hASCs showed significantly attenuated infarct size compared to free hASCs and empty microcapsule group (21.6% ± 1.1% vs. 27.2% ± 3.1% vs. 33.3% ± 3.2%; p < 0.05), enhanced vasculogenesis, and improved cardiac function (fractional shortening: 24.2% ± 2.1% vs. 19.1% ± 0.5% vs. 12.0% ± 4.0%; p < 0.05). These data suggest that microencapsulated hASCs can contribute significantly to the improvement in cardiac functions. Their greater retentions exhibit reduced fibrosis and cardiac dysfunction in experimental animals. However, further research is needed to fully comprehend the underlying biological and immunological effects of microencapsulated hASCs, which jointly play important roles in cardiac repair.en_US
dc.publisherCognizant Communication Corporationen_US
dc.rightsCopyright COGNIZANT, LLC. Creative Commons Attribution Non-Commercial License.
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/
dc.titleGenipin-Cross-Linked Microencapsulated Human Adipose Stem Cells Augment Transplant Retention Resulting in Attenuation of Chronically Infarcted Rat Heart Fibrosis and Cardiac Dysfunctionen_US
dc.typeArticle
kusw.kuauthorPaul, Arghya
kusw.kudepartmentChemical & Petroleum Engren_US
dc.identifier.doi10.3727/096368912X637497
kusw.oaversionScholarly/refereed, publisher version
kusw.oapolicyThis item meets KU Open Access policy criteria.
dc.rights.accessrightsopenAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Copyright COGNIZANT, LLC. Creative Commons Attribution Non-Commercial License.
Except where otherwise noted, this item's license is described as: Copyright COGNIZANT, LLC. Creative Commons Attribution Non-Commercial License.